Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure
June 9, 2016 8:47 AM EDTWedbush maintained a Neutral rating on Fibrocell Science (NASDAQ: FCSC), and cut the price target to $1.50 (from $4.00), as the company reports failure of the azficel-T program. FCSC reported that azficel-T missed the primary endpoints assessing change from baseline at four months in mucosal wave... More
Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord Scarring
June 8, 2016 11:59 AM EDTRoth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced that primary endpoints were not... More
